Title |
Polypharmacy in the HIV-infected older adult population
|
---|---|
Published in |
Clinical Interventions in Aging, June 2013
|
DOI | 10.2147/cia.s37738 |
Pubmed ID | |
Authors |
Lauren J Gleason, Amneris E Luque, Krupa Shah |
Abstract |
The prevalence of human immunodeficiency virus (HIV) infection among people older than 50 years is increasing. Older HIV-infected patients are particularly at risk for polypharmacy because they often have multiple comorbidities that require pharmacotherapy. Overall, there is not much known with respect to both the impact of aging on medication use in HIV-infected individuals, and the potential for interactions with highly active antiretroviral therapy (HAART) and coadministered medications and its clinical consequences. In this review, we aim to provide an overview of polypharmacy with a focus on its impact on the HIV-infected older adult population and to also provide some clinical considerations in this high-risk population. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Spain | 3 | 38% |
United States | 1 | 13% |
France | 1 | 13% |
Unknown | 3 | 38% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Practitioners (doctors, other healthcare professionals) | 4 | 50% |
Members of the public | 3 | 38% |
Scientists | 1 | 13% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Tanzania, United Republic of | 1 | <1% |
Unknown | 147 | 99% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 25 | 17% |
Student > Ph. D. Student | 17 | 11% |
Student > Bachelor | 17 | 11% |
Researcher | 16 | 11% |
Other | 12 | 8% |
Other | 35 | 24% |
Unknown | 26 | 18% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 57 | 39% |
Pharmacology, Toxicology and Pharmaceutical Science | 23 | 16% |
Nursing and Health Professions | 9 | 6% |
Agricultural and Biological Sciences | 4 | 3% |
Social Sciences | 3 | 2% |
Other | 14 | 9% |
Unknown | 38 | 26% |